about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenExplaining oscillations and variability in the p53-Mdm2 systemProteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cellsGlioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressorMyxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent mannerRegulation of ploidy and senescence by the AMPK-related kinase NUAK1DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulationTaspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosisThe miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescenceIdentification and validation of oncogenes in liver cancer using an integrative oncogenomic approachThe expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinomaHedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesisBRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolutionCancer drug resistance: redox resetting renders a wayCancer research in need of a scientific revolution: Using 'paradigm shift' as a method of investigationEvolutionary determinants of cancerMYC and the art of microRNA maintenanceThe FHIT gene product: tumor suppressor and genome "caretaker"Allogeneic tumor cell vaccines: the promise and limitations in clinical trialsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisTurning off AKT: PHLPP as a drug targetThe regulation of the autophagic network and its implications for human diseaseMYC activation is a hallmark of cancer initiation and maintenanceFunctional characterisation of the WW minimal domain for delivering therapeutic proteins by adenovirus dodecahedronGenetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancerStructural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibitionMetastasis: a question of life or deathA SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesisSpy1 expression prevents normal cellular responses to DNA damage: inhibition of apoptosis and checkpoint activationProteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomasThe circadian clock in cancer development and therapyInitiation of genome instability and preneoplastic processes through loss of Fhit expressionIDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulationIdentification of cytotoxic drugs that selectively target tumor cells with MYC overexpressionPhase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans
P2860
Q21092375-2D67BF81-C56F-461E-95FF-4BE791077BCEQ21202791-F49DC38D-56C6-41E7-9ACD-AF459CC67E95Q24294703-53C10CB7-FC0D-44B8-9437-F450C6338A01Q24297086-D097F3A5-B1EE-4432-814F-7FADBED4AFF0Q24299628-1FC9638E-9B45-4DB0-8EFF-127EEAE01858Q24311311-F5C96545-EA08-4C76-8E18-FA6AE6995FE3Q24312129-62BE987C-50CF-44BB-BA2F-EAF50D4A5D5CQ24315089-4EBD5B62-46F3-48E3-932F-E7C763506FDEQ24318723-5852C036-AD2E-431C-90DD-18EEBDB8F63AQ24541560-BA0386DB-F087-4296-B472-B372E6AD3DB1Q24603213-F2578155-7491-40D1-B015-E721660648BBQ24617045-AC375849-4CE4-4DA7-AABD-4936C2775118Q24633776-E3752D09-40B4-4D30-AE25-046738A65002Q24653562-3A0E3796-C4D0-4182-97F7-CE9AB28D7422Q24657777-C5F7A4AF-2EFC-4B75-A0A9-7A82044B9128Q24681977-05F29203-00F2-4336-9812-AD2715D15FECQ25255829-2487DC40-8204-406B-B440-BC60F92C3D04Q26750753-BAB8C8B6-4F68-46E3-959D-8099076EA5BFQ26786406-EA344C27-8297-4EA5-95B7-F47B0E7EBA07Q26801710-98D0D831-5D43-4C9F-BE29-79EB9795843EQ26825457-05BF7E34-F8F9-4952-98B8-098613CCECFDQ26830817-D41EC417-1BFD-42A9-ABD1-D97540EBD85DQ26852333-3D1B5F70-0F2D-4591-8AF9-62F3DDED1142Q26865888-130C5A65-35C9-40D1-9FA6-98EE025421E0Q27014094-A7C9C2D7-1855-4F63-B41A-493EFC556F6FQ27025468-985BA543-0ACB-4F94-8BEA-5DD0E3D6E3F2Q27026026-578DAC67-02D6-4A10-B796-9AAD6C5CCDCFQ27318180-EA1651EC-74D7-4AC4-85E9-D5419353FC7BQ27355520-92E2F7BC-1324-4B10-80D9-24502AE75808Q27649718-D60ED7FA-42A6-4960-B210-5437EA07EDEFQ28237935-35D2286E-4F89-4A5A-A5CA-7CC0E598B248Q28242176-378FD6A9-9C2F-45F7-9DF1-1D84A14CF199Q28255073-6E93D5F0-0DBC-4287-A28A-3CC91DD199B4Q28261764-6D26FC01-79FA-4024-ADA1-C1DF3BCEE5B2Q28308220-59C52615-745A-49D9-B080-37AF883A37BFQ28390451-14E5B9C3-184A-49EE-A4A6-57C7BAE60EC1Q28391562-E4C54547-9323-45CE-A318-0FDC1089CB46Q28396617-9DABC87D-6B74-448D-9025-9A848A9D40EBQ28478132-D3ABC0AE-5380-4B65-8097-2F51AB4D750BQ28482937-98EBAEC6-A848-4D3C-8AD2-E441D1497831
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Intrinsic tumour suppression.
@ast
Intrinsic tumour suppression.
@en
type
label
Intrinsic tumour suppression.
@ast
Intrinsic tumour suppression.
@en
prefLabel
Intrinsic tumour suppression.
@ast
Intrinsic tumour suppression.
@en
P2093
P356
P1433
P1476
Intrinsic tumour suppression.
@en
P2093
Enrique Cepero
Gerard Evan
Scott W Lowe
P2888
P304
P356
10.1038/NATURE03098
P407
P577
2004-11-01T00:00:00Z
P5875
P6179
1014111785